Corbevax

Revisi sejak 2 Agustus 2021 02.10 oleh HsfBot (bicara | kontrib) (Bot: perubahan kosmetika)

Corbevax[1] atau BioE COVID-19, adalah sebuah kandidat vaksin COVID-19 yang dikembangkan oleh firma biofarmasi India Biological E. Limited (BioE), Baylor College of Medicine di Houston, Amerika Serikat, dan perusahaan Amerika Serikat, Dynavax Technologies (DVAX). Vaksin tersebut adalah vaksin subunit protein.[2][3][4][5]

Deskripsi vaksin
Penyakit target SARS-CoV-2
Jenis Subunit protein
Data klinis
Nama dagang Corbevax
Kat. kehamilan ?
Status hukum ?
Rute Intraotot
Pengenal
Kode ATC Tidak ada

Referensi

  1. ^ Bharadwaj, Swati (3 June 2021). "Telangana: Biological E starts at risk manufacturing of Corbevax". The Times of India (dalam bahasa Inggris). Diakses tanggal 2021-06-03. 
  2. ^ "A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease and some amount of sperm in its drug when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Diarsipkan dari versi asli tanggal 12 November 2020. 
  3. ^ "CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate". cepi.net. CEPI. Diakses tanggal 5 March 2021. 
  4. ^ Chui M (16 November 2020). "Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India". Baylor College of Medicine. 
  5. ^ Leo L (16 November 2020). "Biological E initiates human trials of vaccine". Mint. 

Pranala luar



Templat:Vaccine-stub